Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Evaluate more than 400,000 products >>

Featured Jobs

Principal Scientist
Watson Pharmaceuticals - Fort Lauderdale, FL
Clinical Trials Site Director
Lovelace Respiratory Research Institute - Albuquerque, NM
Clinical Research Coordinator
Lovelace Respiratory Research Institute - Albuquerque, NM
Director, IT Global Operation Services, End-User Informatics Job
Celgene Corporation - Summit, NJ, US
Laboratory Facility Manager
International AIDS Vaccine Initiative - New York, NY

More Jobs >>

Events

New Paradigms to Fund & Move Biotech
January 11-12, 2012 — San Francisco, CA
Health Market Science Webinar: 3 Steps to New Physician Opportunities
Nov. 17
Life Science in the Cloud
Nov 16, 2011 — Cambridge, MA
Biomarker Applications for Improved Clinical Trial Outcomes
Nov. 15-16 — Boston

More Events >>

Related Tags >> Vical Oncept Vaccine Merck

Merial Animal Health News

Most Popular Merial Animal Health Story

Merck, Sanofi outline plans for new animal health JV

July 29, 2010 — 9:16am ET | By John Carroll

The newly created Merial-Intervet is being forged by Merck and Sanofi-Aventis into a global powerhouse in the animal health industry, and it will rely heavily on income from some best-selling Read more...

Merial Animal Health Press Releases

GenVec Expands Collaboration With Merial
Sanofi-aventis to Acquire Merck's Interest in Merial
PRESS RELEASE: HSE publishes final report on Foot and mouth outbreak in Surrey

Latest Headlines

Merck, Sanofi outline plans for new animal health JV
July 29, 2010
Vical heralds regulatory approval of melanoma vax for dogs
January 12, 2010

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK